Terpenes in the management of chronic kidney disease

被引:1
|
作者
Kulkarni, Piyusha [1 ]
Yeram, Pranali B. [1 ]
Vora, Amisha [1 ]
机构
[1] Shri Vile Parle Kelavani Mandals Narsee Monjee Ins, Shobhaben Pratapbhai Patel Sch Pharm & Technol Man, Mumbai 400056, India
关键词
Chronic kidney disease (CKD); Terpenes; Renal dysfunction; Acute Kidney Disease (AKI); GLYCATION END-PRODUCTS; DIABETES-MELLITUS; OXIDATIVE STRESS; ANTIINFLAMMATORY ACTIVITY; HYPERTENSION; INJURY; INFLAMMATION; COMPLICATIONS; HYPERGLYCEMIA; EPIDEMIOLOGY;
D O I
10.1007/s00210-024-03098-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic kidney disease (CKD) is a chronic and progressive systemic condition that characterizes irreversible alterations in the kidneys' function and structure over an extended period, spanning months to years. CKD is the one of the major causes of mortality worldwide. However, very limited treatment options are available in the market for management of the CKD. Diabetes and hypertension are the key risk factors for the progression of CKD. It is majorly characterised by glomerulosclerosis, tubular atrophy, and interstitial fibrosis. Plants are considered safe and effective in treating various chronic conditions. A diverse group of phytoconstituents, including polyphenols, flavonoids, alkaloids, tannins, saponins, and terpenes, have found significant benefits in managing chronic ailments. Terpenes constitute a diverse group of plant compounds with various therapeutic benefits. Evidence-based pharmacological studies underscore the crucial role played by terpenes in preventing and managing CKD. These substances demonstrate the capacity to hinder detrimental pathways, such as oxidative stress, inflammation and fibrosis, thereby demonstrating benefit in renal dysfunction. This review offers a comprehensive overview of the roles and positive attributes of commonly occurring terpenes in managing the causes and risk factors of CKD and the associated conditions.
引用
收藏
页码:6351 / 6368
页数:18
相关论文
共 50 条
  • [41] Acute Management of Patients With Chronic Kidney Disease
    Stratton, Shannon
    Yam, Lily
    Gohil, Krupa
    Remigio, Adrianne
    Tsu, Laura V.
    US PHARMACIST, 2014, 39 (08) : 56 - 60
  • [42] Management of osteoporosis in patients with chronic kidney disease
    M. Abdalbary
    M. Sobh
    S. Elnagar
    M. A. Elhadedy
    N. Elshabrawy
    M. Abdelsalam
    K. Asadipooya
    A. Sabry
    A. Halawa
    A. El-Husseini
    Osteoporosis International, 2022, 33 : 2259 - 2274
  • [43] Primary Care Management of Chronic Kidney Disease
    Adrienne S. Allen
    John P. Forman
    E. John Orav
    David W. Bates
    Bradley M. Denker
    Thomas D. Sequist
    Journal of General Internal Medicine, 2011, 26 : 386 - 392
  • [44] Chronic Kidney Disease Diagnosis and Management: A Review
    Chen, Teresa K.
    Knicely, Daphne H.
    Grams, Morgan E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (13): : 1294 - 1304
  • [45] Advances in chronic kidney disease pathophysiology and management
    Usherwood, Tim
    Lee, Vincent
    AUSTRALIAN JOURNAL OF GENERAL PRACTICE, 2021, 50 (04) : 188 - 192
  • [46] Management and treatment of chronic kidney disease in cats
    Caney, Sarah
    IN PRACTICE, 2016, 38 : 10 - 13
  • [47] Chronic kidney disease in adults: assessment and management
    Forbes, Anna
    Gallagher, Hugh
    CLINICAL MEDICINE, 2020, 20 (02) : 128 - 132
  • [48] Primary Care Management of Chronic Kidney Disease
    Allen, Adrienne S.
    Forman, John P.
    Orav, E. John
    Bates, David W.
    Denker, Bradley M.
    Sequist, Thomas D.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2011, 26 (04) : 386 - 392
  • [49] Management and treatment of patients with chronic kidney disease
    Endoh, M
    INTERNAL MEDICINE, 2005, 44 (04) : 389 - 391
  • [50] Beta blockers in the management of chronic kidney disease
    Bakris, G. L.
    Hart, P.
    Ritz, E.
    KIDNEY INTERNATIONAL, 2006, 70 (11) : 1905 - 1913